Need help navigating aged care? Explore our support services
Aged Care Home
Support at Home
Retirement Living
Finance & Placement Advice
Healthcare Equipment
Mobility and Equipment
Patient care equipment
Skin and wound Care
Safety and Security
Assessments
Assistive Technology
End of Life
Financial Services
Funerals
Placement Consultants
Advocacy
No results found
No results found
No results found
Advanced Filters
Distance (proximity)
Price Range
RAD (Refundable Accommodation Deposit) is a lump-sum payment for aged care homes. It is fully refundable when the resident leaves, as long as there are no outstanding fees.
Min RAD
Any
$250,000
$500,000
$750,000
$1,000,000
$1,500,000
$1,750,000
$2,000,000
Maximum RAD
Any
$250,000
$500,000
$750,000
$1,000,000
$1,500,000
$1,750,000
$2,000,000
Facility size
Based on how many beds the facilty has.
Any
Small
Medium
Large
Service Delivery
Services offered at a location or in a region
Any
On Site
Service Region
Features
Single rooms with ensuites
Respite beds
Extra service beds
Secure dementia beds
24/7 Registered nursing
Full or Partially government funded
Couples accommodation
Facility has pets
Non-dedicated respite
Palliative care
Partner considered without ACAT
Secure garden
Transition care
Cafe/Kiosk
Chapel/Church
Hairdressing Salon
Facility Owned Transport
Single Rooms
Rooms with ensuites
Registered nursing
Non secure dementia care
Diversional therapy
Medication supervision
Respite care
Secure access
Small pets considered

‘Everyday’ meds to treat Alzheimer’s

Medications used to treat hypertension, diabetes and skin conditions could be doubling as treatments for Alzheimer’s within a decade, according to UK researchers. Led by King’s College London, the research identified four existing drugs and one drug class which could reduce risk or slow down symptoms of the disease.

Posted
by Grace Mindwell

Medications used to treat hypertension, diabetes and skin conditions could be doubling as treatments for Alzheimer’s within a decade, according to UK researchers.

Led by King’s College London, the research identified four existing drugs and one drug class which could reduce risk or slow down symptoms of the disease.

Published in Nature Reviews Drug Discovery journal last week, the drugs or classes of drugs identified as potential Alzheimer’s treatments by the study included:

  • High blood pressure medications – including Nilvadipine – from the calcium channel blockers family.
  • Diabetes medications exenatide and liraglutide, which stimulate the brain and have been shown to reduce the formation of plaques on the brain.
  • Minocycline, a tetracycline antibiotic used to treat acne.
  • Acitretin, a drug used to treat psoriasis, which researchers have shown to modify the way proteins linked to dementia form.

Lead author, Professor Clive Ballard, who is Director of Research at Alzheimer’s Society and Professor of Age Related Diseases at King’s College London, said: “Defeating dementia is one of the biggest challenges facing both medicine and society as a whole. Developing new drugs to treat the condition is incredibly important, but comes with a huge price tag and, for those affected by dementia, an unimaginable wait.

“This study identifies existing treatments and shows the potential to identify other similar drugs which are safe and if effective in clinical trials could be used to treat Alzheimer’s disease in 10 years or less.”

More research to increase the understanding of how these drugs work, and how they could be used to treat Alzheimer’s, is underway.

Researchers warn people should not take these drugs for anything other than the conditions they are prescribed for as more research is needed.

Read next

Sign up or log in with your phone number
Phone
Enter your phone number to receive a verification notification
Aged Care Guide is endorsed by
COTA logo
ACIA logo